On the public citation graph

In vitro and in vivo Biological Evaluation of Newly Tacrine-Selegiline Hybrids as Multi-Target Inhibitors of Cholinesterases and Monoamine Oxidases for Alzheimer’s Disease

0 signed · 55 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.

Claim with ORCID

Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.

See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1007/bf00432208openalex-snapshot

Alzheimer's disease and senile dementia: Biochemical characteristics and aspects of treatment

inferredcites →https://doi.org/10.1007/bf02815095openalex-snapshot

Ultrastructural localization of butyrylcholinesterase in senile plaques in the brains of aged and Alzheimer disease patients

inferredcites →https://doi.org/10.1007/s00204-019-02538-yopenalex-snapshot

Management of oxidative stress and other pathologies in Alzheimer’s disease

inferredcites →https://doi.org/10.1016/0006-2952(61)90145-9openalex-snapshot

A new and rapid colorimetric determination of acetylcholinesterase activity

inferredcites →https://doi.org/10.1016/0006-2952(88)90356-5openalex-snapshot

Hepatotoxicity of tetrahydroaminoacridine in isolated rat hepatocytes: Effect of glutathione and vitamin E

inferredcites →https://doi.org/10.1016/0014-2999(94)00710-oopenalex-snapshot

Dynorphin A-(1–13) potently improves scopolamine-induced impairment of passive avoidance response in mice

inferredcites →https://doi.org/10.1016/j.arr.2023.101996openalex-snapshot

Passive Alzheimer’s immunotherapy: A promising or uncertain option?

inferredcites →https://doi.org/10.1016/j.bioorg.2018.09.010openalex-snapshot

Coumarin-dithiocarbamate hybrids as novel multitarget AChE and MAO-B inhibitors against Alzheimer’s disease: Design, synthesis and biological evaluation

inferredcites →https://doi.org/10.1016/j.bioorg.2019.02.008openalex-snapshot

Investigation of inhibitory properties of some hydrazone compounds on hCA I, hCA II and AChE enzymes

inferredcites →https://doi.org/10.1016/j.bioorg.2019.103027openalex-snapshot

Novel chromanone-dithiocarbamate hybrids as multifunctional AChE inhibitors with β-amyloid anti-aggregation properties for the treatment of Alzheimer’s disease

inferredcites →https://doi.org/10.1016/j.bioorg.2022.106224openalex-snapshot

Novel AP2238-clorgiline hybrids as multi-target agents for the treatment of Alzheimer's disease: Design, synthesis, and biological evaluation

inferredcites →https://doi.org/10.1016/j.ejmech.2009.02.031openalex-snapshot

Knowledge based identification of MAO-B selective inhibitors using pharmacophore and structure based virtual screening models

inferredcites →https://doi.org/10.1016/j.ejmech.2013.01.039openalex-snapshot

A novel series of tacrine–selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease

inferredcites →https://doi.org/10.1016/j.ejmech.2017.02.039openalex-snapshot

Design, synthesis and evaluation of novel ferulic acid- O -alkylamine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease

inferredcites →https://doi.org/10.1016/j.ejmech.2017.03.062openalex-snapshot

Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease

inferredcites →https://doi.org/10.1016/j.ejmech.2018.01.055openalex-snapshot

Design, synthesis and biological evaluation of new coumarin-dithiocarbamate hybrids as multifunctional agents for the treatment of Alzheimer's disease

inferredcites →https://doi.org/10.1016/j.ejmech.2018.02.023openalex-snapshot

Novel Tacrine-Hydroxyphenylbenzimidazole hybrids as potential multitarget drug candidates for Alzheimer's disease

inferredcites →https://doi.org/10.1016/j.ejmech.2019.05.020openalex-snapshot

Multi-target design strategies for the improved treatment of Alzheimer's disease

inferredcites →https://doi.org/10.1016/j.ejmech.2019.07.045openalex-snapshot

Rapid generation of novel benzoic acid–based xanthine derivatives as highly potent, selective and long acting DPP-4 inhibitors: Scaffold-hopping and prodrug study

inferredcites →https://doi.org/10.1016/j.ejmech.2020.112475openalex-snapshot

Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer’s disease

inferredcites →https://doi.org/10.1016/j.ejphar.2020.173554openalex-snapshot

Alzheimer's disease: Recent treatment strategies

inferredcites →https://doi.org/10.1016/j.jalz.2016.03.001openalex-snapshot

2016 Alzheimer's disease facts and figures

inferredcites →https://doi.org/10.1016/j.pharmthera.2014.02.010openalex-snapshot

Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: Focus on modulation of CNS monoamine neurotransmitter release

inferredcites →https://doi.org/10.1016/s0140-6736(10)61349-9openalex-snapshot

Alzheimer's disease

inferredcites →https://doi.org/10.1016/s0140-6736(20)32205-4openalex-snapshot

Alzheimer's disease

inferredcites →https://doi.org/10.1016/s0223-5234(03)00012-6openalex-snapshot

High throughput artificial membrane permeability assay for blood–brain barrier

inferredcites →https://doi.org/10.1016/s1474-4422(03)00502-7openalex-snapshot

Treatment of Alzheimer's disease; current status and new perspectives

inferredcites →https://doi.org/10.1016/s2468-2667(21)00249-8openalex-snapshot

Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019

inferredcites →https://doi.org/10.1021/acs.jmedchem.0c01129openalex-snapshot

Discovery and Biological Evaluation of a Novel Highly Potent Selective Butyrylcholinsterase Inhibitor

inferredcites →https://doi.org/10.1021/acs.jmedchem.5b00599openalex-snapshot

Structure-Based Design and Optimization of Multitarget-Directed 2H-Chromen-2-one Derivatives as Potent Inhibitors of Monoamine Oxidase B and Cholinesterases

inferredcites →https://doi.org/10.1021/acs.jmedchem.5b01325openalex-snapshot

Tacrine–Trolox Hybrids: A Novel Class of Centrally Active, Nonhepatotoxic Multi-Target-Directed Ligands Exerting Anticholinesterase and Antioxidant Activities with Low In Vivo Toxicity

inferredcites →https://doi.org/10.1021/acs.jmedchem.8b00697openalex-snapshot

LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism

inferredcites →https://doi.org/10.1021/jm200716yopenalex-snapshot

Synthesis and Study of a Series of 3-Arylcoumarins as Potent and Selective Monoamine Oxidase B Inhibitors

inferredcites →https://doi.org/10.1021/jm200853topenalex-snapshot

Synthesis, Biological Evaluation, and Molecular Modeling of Donepezil and N-[(5-(Benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine Hybrids as New Multipotent Cholinesterase/Monoamine Oxidase Inhibitors for the Treatment of Alzheimer’s Disease

inferredcites →https://doi.org/10.1021/tx010073bopenalex-snapshot

Interactions of Nitrogen-Containing Xenobiotics with Monoamine Oxidase (MAO) Isozymes A and B: SAR Studies on MAO Substrates and Inhibitors

inferredcites →https://doi.org/10.1038/s41593-020-00735-yopenalex-snapshot

Severe reactive astrocytes precipitate pathological hallmarks of Alzheimer’s disease via H2O2− production

inferredcites →https://doi.org/10.1056/nejme2103722openalex-snapshot

Progress with Treatments for Alzheimer’s Disease

inferredcites →https://doi.org/10.1136/bmj.2.6150.1457openalex-snapshot

Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia.

inferredcites →https://doi.org/10.1177/0091270011406279openalex-snapshot

The Monoamine Oxidase Type B Inhibitor Rasagiline in the Treatment of Parkinson Disease: Is Tyramine a Challenge?

inferredcites →https://doi.org/10.1212/wnl.0000000000008239openalex-snapshot

Low-dose ladostigil for mild cognitive impairment

inferredcites →https://doi.org/10.1517/14740338.2014.914168openalex-snapshot

Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine

inferredcites →https://doi.org/10.2174/092986710791111206openalex-snapshot

Tacrine Derivatives and Alzheimers Disease

inferredcites →https://doi.org/10.2174/138161210793176527openalex-snapshot

Monoamine Oxidase Inhibitors as Neuroprotective Agents in Age-Dependent Neurodegenerative Disorders

inferredcites →https://doi.org/10.2174/1570159x16666180412091908openalex-snapshot

Therapeutic Potential of Multifunctional Tacrine Analogues

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.3897/pharmacia.72.e164727zenodo-depositor-declared

Multi-target monoamine oxidase-B (MAO-B) inhibitors in the treatment of Parkinson’s disease

inferred← citeshttps://doi.org/10.1002/cbdv.202402837openalex-snapshot

Recent Studies on Heterocyclic Cholinesterase Inhibitors Against Alzheimer's Disease

inferred← citeshttps://doi.org/10.1016/j.bmc.2026.118677openalex-snapshot

Development of tacrine-based multitarget-directed ligands as dual AChE/EGFR inhibitors with neuroprotective activity

inferred← citeshttps://doi.org/10.1016/j.ejmcr.2025.100294openalex-snapshot

Molecules with alkyne fragment in medicinal chemistry: The path from neurotoxins to drugs

inferred← citeshttps://doi.org/10.1016/j.ejphar.2025.177886openalex-snapshot

Optimizing the structure of repurposed metformin can improve anti-cholinesterase and anti-amyloidogenic effects

inferred← citeshttps://doi.org/10.1039/d5md00626kopenalex-snapshot

Investigation of the multifunctional profile of dihydroquinazoline derivatives as potential therapeutics for Alzheimer's disease

inferred← citeshttps://doi.org/10.1039/d6ra06124aopenalex-snapshot

Quinazolinone–triazole hybrids as multi-target-directed ligands for Alzheimer's disease: discovery of potent and selective MAO-B inhibitors with cholinesterase modulating activity

inferred← citeshttps://doi.org/10.2174/0113894501365588250131073304openalex-snapshot

Targeting Neurodegeneration: The Emerging Role of Hybrid Drugs

inferred← citeshttps://doi.org/10.3390/cimb48030334openalex-snapshot

Neurotransmitter Systems in Alzheimer’s Disease

inferred← citeshttps://doi.org/10.3390/life14121555openalex-snapshot

Therapeutic Options in Alzheimer’s Disease: From Classic Acetylcholinesterase Inhibitors to Multi-Target Drugs with Pleiotropic Activity

inferred← citeshttps://doi.org/10.3390/ph18060831openalex-snapshot

Multitarget Compounds Designed for Alzheimer, Parkinson, and Huntington Neurodegeneration Diseases

Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.